Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:19 2026-05-07 pm EDT			5-day change	1st Jan Change
112.30 ^USD	-1.11%		+2.86%	+6.69%

May. 07	The Rally Spreads
May. 05	Merck Completes Terns Pharmaceuticals Acquisition	MT

Merck Gets European OK for Enflonsia in Infants During First RSV Season

Published on 04/17/2026 at 09:59 am EDT - Modified on 04/17/2026 at 10:00 am EDT

Dow Jones

MERCK & CO., INC.

-1.11%

By Colin Kellaher

Merck & Co. has won European Commission approval of its Enflonsia immunization for the prevention of respiratory syncytial virus, or RSV, in newborns and infants during their first RSV season.

The Rahway, N.J., drugmaker on Friday said the green light makes Enflonsia the first and only RSV preventive option in Europe for administration to infants using the same dose regardless of weight.

RSV, a contagious virus that is the leading cause of hospitalization for healthy infants, can cause inflammation in the airways, leading to difficulty breathing.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

04-17-26 0958ET

Latest news about Merck & Co., Inc.

May. 07	The Rally Spreads
May. 05	Merck Completes Terns Pharmaceuticals Acquisition	MT
May. 04	Global pharma companies that have publicly announced Trump drug pricing agreements	RE
May. 01	Goldman Sachs Adjusts Merck Price Target to $137 From $133	MT
May. 01	Wells Fargo Adjusts Merck Price Target to $145 From $150	MT
May. 01	Big Pharma M&A set for mega year as patent expiries drive deal urgency	RE
May. 01	Morgan Stanley Raises Price Target on Merck to $112 From $109, Keeps Equalweight Rating	MT
May. 01	Moderna first-quarter revenue jumps on strong overseas COVID vaccine sales	RE
Apr. 30	S&P 500, Nasdaq on course for best month since 2020 despite Middle East risks	RE
Apr. 30	Wall St set to climb at open as earnings optimism overshadows oil woes	RE
Apr. 30	Wall St futures climb as investors balance earnings optimism against oil woes	RE
Apr. 30	Merck beats quarterly sales expectations as Keytruda fuels growth	RE
Apr. 30	Merck Q1 adjusted loss per share $1.28 versus IBES estimate $-1.51	RE
Apr. 30	S&P 500, Nasdaq on course for best month since 2020 despite Middle East risks	RE
Apr. 30	Merck posts quarterly loss due to Cidara charge, sales rise 5%	RE

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (73.9%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (15.5%); - sale of animal health products (9.8%); - other (0.8%). Net sales are distributed geographically as follows: the United States (56.2%), Europe/Middle East/Africa (22.4%), Latin America (5.2%), Asia/Pacific (4.6%), Japan (4.2%), China (3%) and other (4.4%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

May. 14 -

More about the company